|Description||GSK 269962 is a potent ROCK inhibitor with IC50 values are 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively, which displays greater than 30-fold selectivity for ROCK against a panel of serine/threonine kinases. It may be used in OAB treatment. It has been shown to block the generation of inflammatory cytokines in lipopolysaccharide-stimulated monocytes and to induce vasorelaxation in preconstricted rat aorta (IC50 = 35 nM). It lowers blood pressure in a rat model of hypertension. It induced a reduction in blood pressure of approximately 10, 20, and 50 mm Hg at doses of 1, 3, and 30 mg/kg. It represent a novel class of ROCK inhibitors that have profound effects in the vasculature, which may enable us to further evaluate the potential beneficial effects of ROCK inhibition in animal models of cardiovascular as well as other chronic diseases.|
|Solubility||10 mM in DMSO|
|Application||GSK 269962 may be used in OAB treatment. It represent a novel class of ROCK inhibitors.|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Density||1.45±0.1 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr|
LX7101, a pyrrolopyrimidine derivative, is a LIM domain kinase 2 (LIMK2) inhibitor which could be probably effective in the treatment of glaucoma. It has just f...
GSK180736A is a selective GRK2 inhibitor with an IC50 of 0.77 μM. It is also a weak inhibitor of PKA with an IC50 of 30 μM, but highly potent against ROCK1 (IC5...
ZINC00881524 is a specific ROCK inhibitor.
(S)-H-1152 dihydrochloride is a Rho-kinase inhibitor and cell permeable inhibitor of ROCK (Ki = 1.6 nM).
Verosudil is a selective Rho-kinase inhibitor originated by Aerie Pharmaceuticals. In Jun 2013, Phase-II for Ocular hypertension in USA was discontinued. In Sep...
SAR-407899 hydrochloride is the hydrochloride form of SAR-407899, which is a potent, ATP-competitive ROCK inhibitor. It has good antihypertensive activity.
KD025 is an orally available, and selective ROCK2 inhibitor with IC50 and Ki of 60 nM and 41 nm, respectively. Phase 2.
SB 772077B dihydrochloride
SB 772077B dihydrochloride is a potent Rho-kinase (ROCK) inhibitor (IC50 ~ 5.6 nM at recombinant human ROCK1 and 2) exhibiting potent vasodilator activity. SB 7...
C-1 is a protein kinase inhibitor selecitive for PKG, PKA and PKC (IC50 = 4, 8 and 12 µM, respectively) and is widely used as a ROCK inhibitor.
H-1152 Dihydrochloride is a cell-permeable isoquinolinesulfonamide compound that acts as a highly specific, potent, and ATP-competitive inhibitor of G-protein R...
K-115, also called as Ripasudil or Glanatec, a selective ROCK inhibitor (IC50 =31 nM), is a promising emerging antiglaucoma drug, and was thus approved by the J...
Y-33075 dihydrochloride is a selective ROCK inhibitor (IC50= 3.6nM) derived from Y-27632, and is more potent than Y-27632.
Y-27632 2HCl inhibits ROCK-II while displaying little activity against PKC, cAMP-dependent protein kinase and myosin light-chain kinase (MLCK) with Ki of 26 μM,...
Chroman 1, a chroman-based compound, is an effective ROCK II inhibitor which could probably influence the cell motility involved in sorts of disorders.
A potent inhibitor of ROCK2 (IC50= 1.2 nM)
Fasudil HCl, a 5-isoquinolinesulfonamide derivative, is a highly selective Rho-associated protein kinase inhibitor that might have a rate in romoting the recove...
Hydroxyfasudil, formed through the metabolism action of Fasudil, could be useful in improving the symptoms of pulmonary hypertension for playing the role as an ...